Open AccessP1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL‐DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
Author(s) -
Zinzani P. L.,
Ansell S. M.,
Bosch F.,
Friedberg J. W.,
Marolleau J. P.,
Arcaini L.,
GarciaSanz R.,
Gopal A. K.,
Grande C.,
Merryman R.,
Pinto A.,
Smith S. D.,
Villasboas J. C.,
Wallace D.,
Fagerberg J.,
Magalhaes J. G.,
Armand P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847328.48663.29
Subject(s) - lenalidomide , rituximab , medicine , oncology , peptide vaccine , cd20 , immunology , lymphoma , epitope , antibody , multiple myeloma